Sign up
Pharma Capital

Benchmark CFO to step down

The aquaculture and genetics firm said Mark Plampin would continue in the role until a successor was found to ensure an orderly transition process
Board room table
An external search for a new CFO has already commenced

Benchmark Holdings PLC’s (LON:BMK) has announced that Mark Plampin will step down from his current role as chief financial officer to pursue other opportunities.

The aquaculture and genetics firm said Plampin would continue in the role until a successor was found to ensure an orderly transition process.

WATCH: Benchmark Holdings well placed to deliver on its five-year strategy

Benchmark added that an external search for a new CFO had commenced and a further announcement would be made “in due course”.

“I am proud of the significant milestones achieved during my time at Benchmark. We now have a focused pipeline of products and the infrastructure in place to support the Group's sustainable growth. I have enjoyed being part of a strong team at Benchmark and I look forward to working with my successor to ensure a smooth handover”, Plampin said.

Benchmark's Chairman, Peter George, added: "On behalf of the Board, I would like to take this opportunity to thank Mark for his considerable contribution during his time with the Group and wish him every success in the future.

"We have begun the search for his successor and look forward to updating on progress and ensuring a smooth handover of duties in due course."


In early trading on Tuesday, Benchmark shares were 1.8% lower at 49.6p.

View full BMK profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.